The World Health Organization (WHO) Global Tuberculosis Programme has initiated a process for the collection and assessment of evidence on whether the dosing of rifampicin, isoniazid, ethambutol and pyrazinamide requires further optimization to safely improve treatment success and reduce unfavourable treatment outcomes in TB patients on first-line treatment regimens.
Post a Comment